Promising Phase IIa Results and Favorable Safety Profile Drive Buy Rating for Skye Bioscience’s Nimacimab
I'm PortAI, I can summarize articles.
Andy Hsieh has issued a Buy rating for Skye Bioscience’s nimacimab following promising Phase IIa trial results, particularly its combination with Wegovy, which showed significant weight loss. Despite not meeting the primary endpoint as a monotherapy, nimacimab's favorable safety profile, with no serious adverse events and low discontinuation rates, supports its tolerability. Skye's plans for higher dosing strategies and further trial results presentation enhance the positive outlook. H.C. Wainwright also initiated coverage with a Buy rating and a $20.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments